Form 8-K - Current report:
SEC Accession No. 0001664710-25-000033
Filing Date
2025-04-10
Accepted
2025-04-10 06:01:19
Documents
16
Period of Report
2025-04-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20250409.htm   iXBRL 8-K 66427
2 EX-3.1 exhibit314925.htm EX-3.1 32952
3 EX-4.1 exhibit41492025.htm EX-4.1 368600
4 EX-99.1 exhibit99141025pr.htm EX-99.1 16098
  Complete submission text file 0001664710-25-000033.txt   705050

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250409.xsd EX-101.SCH 1782
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250409_lab.xml EX-101.LAB 23451
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250409_pre.xml EX-101.PRE 13581
18 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250409_htm.xml XML 2923
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 25826358
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)